Literature DB >> 26169933

miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy.

Shiqian Gao1, Huayu Tian2, Ye Guo3, Yuce Li2, Zhaopei Guo2, Xiaojuan Zhu3, Xuesi Chen4.   

Abstract

MicroRNA-21 (miR-21) inhibition is a promising biological strategy for breast cancer therapy. However its application is limited by the lack of efficient miRNA inhibitor delivery systems. As a cationic polymer transfection material for nucleic acids, the poly (l-lysine)-modified polyethylenimine (PEI-PLL) copolymer combines the high transfection efficiency of polyethylenimine (PEI) and the good biodegradability of polyllysine (PLL). In this work, PEI-PLL was successfully synthesized and confirmed to transfect plasmid and oligonucleotide more effectively than PEI in MCF-7 cells (human breast cancer cells). In this regard, two kinds of miR-21 inhibitors, miR-21 sponge plasmid DNA (Sponge) and anti-miR-21 oligonucleotide (AMO), were transported into MCF-7 cells by PEI-PLL respectively. The miR-21 expression and the cellular physiology were determined post transfection. Compared with the negative control, PEI-PLL/Sponge or PEI-PLL/AMO groups exhibited lower miR-21 expression and cell viability. The anti-tumor mechanism of PEI-PLL/miR-21 inhibitors was further studied by cell cycle and western blot analyses. The results indicated that the miR-21 inhibition could induce the cell cycle arrest in G1 phase, upregulate the expression of Programmed Cell Death Protein 4 (PDCD4) and thus active the caspase-3 apoptosis pathway. Interestingly, the PEI-PLL/Sponge and PEI-PLL/AMO also sensitized the MCF-7 cells to anti-tumor drugs, doxorubicin (DOX) and cisplatin (CDDP). These results demonstrated that PEI-PLL/Sponge and PEI-PLL/AMO complexes would be two novel and promising gene delivery systems for breast cancer gene therapy based on miR-21 inhibition. STATEMENT OF SIGNIFICANCE: This work was a combination of the high transfection efficiency of polyethylenimine (PEI), the good biodegradability of polyllysine (PLL) and the breast cancer-killing effect of miR-21 inhibitors. The poly (l-lysine)-modified polyethylenimine (PEI-PLL) copolymer was employed as the vector of miR-21 sponge plasmid DNA (Sponge) or anti-miR-21 oligonucleotide (AMO). PEI-PLL showed more transfection efficiency and lower cytotoxicity in human breast cancer cells than PEI. Moreover, the breast cancer cells exhibited significantly lower miR-21 expression and cell viability post transfection with sponge or AMO. Interestingly, the PEI-PLL/miR-21 inhibitor complexes also sensitized the cancer cells to anti-cancer chemotherapy drugs, doxorubicin (DOX) and cisplatin (CDDP). This synergistic effect provides a good application prospect of co-delivery miR-21 inhibitors and chemical drugs in breast cancer therapy.
Copyright © 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer therapy; MiRNA-21 AMO; MiRNA-21 sponge; Polyethylenimine; Polylysine

Mesh:

Substances:

Year:  2015        PMID: 26169933     DOI: 10.1016/j.actbio.2015.07.020

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  31 in total

1.  Synthesis and Evaluation of Chloroquine-Containing DMAEMA Copolymers as Efficient Anti-miRNA Delivery Vectors with Improved Endosomal Escape and Antimigratory Activity in Cancer Cells.

Authors:  Ying Xie; Fei Yu; Weimin Tang; Bolutito Oluwole Alade; Zheng-Hong Peng; Yazhe Wang; Jing Li; David Oupický
Journal:  Macromol Biosci       Date:  2017-08-04       Impact factor: 4.979

Review 2.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

3.  MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.

Authors:  W He; C Wang; R Mu; P Liang; Z Huang; J Zhang; L Dong
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

4.  Discriminating cirRNAs from other lncRNAs using a hierarchical extreme learning machine (H-ELM) algorithm with feature selection.

Authors:  Lei Chen; Yu-Hang Zhang; Guohua Huang; Xiaoyong Pan; ShaoPeng Wang; Tao Huang; Yu-Dong Cai
Journal:  Mol Genet Genomics       Date:  2017-09-14       Impact factor: 3.291

5.  Polymer nanocarriers for MicroRNA delivery.

Authors:  Chintan H Kapadia; Benjamin Luo; Megan N Dang; N'Dea Irvin-Choy; Danielle M Valcourt; Emily S Day
Journal:  J Appl Polym Sci       Date:  2019-11-12       Impact factor: 3.125

Review 6.  Delivery of therapeutic miRNA using polymer-based formulation.

Authors:  Eunmi Ban; Taek-Hyun Kwon; Aeri Kim
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

Review 7.  Host miRNA and immune cell interactions: relevance in nano-therapeutics for human health.

Authors:  Yogesh Sharma; Adesh K Saini; Sheetal Kashyap; Gourav Chandan; Narinder Kaur; Vijai Kumar Gupta; Vijay Kumar Thakur; Vipin Saini; Reena V Saini
Journal:  Immunol Res       Date:  2021-10-29       Impact factor: 2.829

Review 8.  Dissecting the Roles of PDCD4 in Breast Cancer.

Authors:  Qian Cai; Hsin-Sheng Yang; Yi-Chen Li; Jiang Zhu
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 9.  Production and clinical development of nanoparticles for gene delivery.

Authors:  Jie Chen; Zhaopei Guo; Huayu Tian; Xuesi Chen
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-06       Impact factor: 6.698

Review 10.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.